Nasal congestion

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kenvue Inc. - KVUE

Retrieved on:

Monday, November 13, 2023

Food and Drug Administration, Nasal congestion, NYSE, Johnson & Johnson, Food, LLP, Nasal, Phenylephrine, FDA, IPO, News, Prior, Pomerantz

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE).

Key Points:

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Kenvue and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on:

Monday, November 13, 2023

Defendant, KVUE, Suite, Nasal congestion, NYSE, Johnson & Johnson, Risk, Nasal, Phenylephrine, GPM, Registration statement, FDA, Prospectus, Register, Court, News, Security (finance), Pharmaceutical industry, IPO

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

Retrieved on:

Saturday, December 9, 2023

The majority of adverse events in treated patients were attributed to underlying sickle cell disease or conditioning with busulfan.

Key Points:

The majority of adverse events in treated patients were attributed to underlying sickle cell disease or conditioning with busulfan.
Lovo-cel is the most deeply studied gene therapy in development for sickle cell disease, with the most patients treated and longest follow-up in the field.
As of February 13, 2023, 59 patients were treated across the entire clinical development program with follow-up beyond 8 years in the earliest treated patients.
In sickle cell disease, hemolysis happens too quickly due to the fragility of sickled red blood cells, resulting in hemolytic anemia.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on:

Thursday, December 7, 2023

In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.

Key Points:

In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2023, injuring investors.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

ENT Laser Devices Market to grow by USD 119.6 million from 2022 to 2027; North America to account for 40% of market growth - Technavio

Retrieved on:

Thursday, November 23, 2023

NEW YORK, Nov. 23, 2023 /PRNewswire/ -- The ENT laser devices market is expected to grow by USD 119.6 million from 2022 to 2027.

Key Points:

NEW YORK, Nov. 23, 2023 /PRNewswire/ -- The ENT laser devices market is expected to grow by USD 119.6 million from 2022 to 2027.
The ENT devices market is estimated to grow by USD 8.83 billion at a CAGR of 6.34% between 2022 and 2027.
Detailed information on factors that will drive the growth of the ENT laser devices market between 2022 and 2027.
Growth of the ENT laser devices market across North America, Europe, Asia, and ROW
Comprehensive analysis of factors that will challenge the growth of ENT laser devices market companies.

Bryn Pharma to Present Positive Clinical Data Supporting Use of Its Epinephrine Nasal Spray in Adults with or without Congestion at 2023 ACAAI Annual Meeting

Retrieved on:

Thursday, November 9, 2023

LEBANON, N.J., Nov. 9, 2023 /PRNewswire/ -- Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a novel and convenient way for patients and caregivers to treat anaphylaxis, announced today that positive clinical data supporting use of its epinephrine nasal spray (ENS) – known as NDS1C – in adults with or without congestion, will be presented during the 2023 American College of Allergy Asthma and Immunology Annual Scientific Meeting (ACAAI). The meeting is being held November 9-13, 2023, in Anaheim, California.

Key Points:

The results showed that NDS1C, in fact, provides enhanced absorption in adults with or without congestion compared to intramuscular (IM) epinephrine and the epinephrine autoinjector (EAI).
"Unlike other epinephrine nasal spray candidates in development, NDS1C is the only intranasal epinephrine product with publicly available data demonstrating enhanced absorption in the presence of congestion.
In the first period, both cohorts received 13.2 mg of NDS1C administered by two consecutive sprays, with congestion induced by NAC.
The poster can be accessed here and presentations details are as follows:
Date & Time: Friday, November 10 at 3:15 p.m. PT

Kenvue Inc.: Please contact the Portnoy Law Firm to recover your losses; December 8, 2023 deadline.

Retrieved on:

Tuesday, November 7, 2023

FDA, IPO, Register, NYSE, KVUE, Decongestant, Registration statement, News, PE, Phenylephrine, Prospectus, Risk, Nasal congestion, Johnson & Johnson, Defendant, Security (finance), Pharmaceutical industry

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) investors that a lawsuit filed on behalf of investors that purchased Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2023 initial public offering (the “IPO” or “Offering”).

Key Points:

Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
However, shortly after the IPO, an FDA panel unanimously declared that oral forms of PE were ineffective in relieving nasal congestion.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on:

Monday, November 6, 2023

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kenvue Inc. - KVUE

Retrieved on:

Sunday, November 5, 2023

FDA, IPO, Nasal, NYSE, Food, Prior, News, PE, Pomerantz, LLP, Phenylephrine, Nasal congestion, Johnson & Johnson, Food and Drug Administration, Pharmaceutical industry

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE).

Key Points:

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Kenvue and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on:

Tuesday, October 31, 2023

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles